EDG-5440

EDG-5440 is an investigational **orally bioavailable small molecule** developed by **Edgewise Therapeutics** for rare **neuromuscular diseases**. Public company disclosures describe it as a **next-generation skeletal muscle myosin ATPase modulator** designed to target skeletal muscle in a specific subset of rare neuromuscular disorders. The program appears to have remained **preclinical** and has subsequently been reported as **discontinued**. Detailed target-level pharmacology, precise molecular target annotation, formulation specifics, and clinical dosing information have not been publicly disclosed in the sources reviewed.